References
- Baggio, L. L., & Drucker, D. J. (2021). Glucagon-like peptide-1 receptor agonists: Mechanisms of action and therapeutic applications. Cell Metabolism, 33(4), 740-755.
- Cummings, D. E., & Rubino, F. (2018). Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia, 61(2), 257-264.
- Groll, D. L., & Wexler, D. J. (2023). Tirzepatide: A novel dual agonist for the treatment of type 2 diabetes and obesity. Lancet Diabetes&Endocrinology, 11(1), 55-67.
- Rabe, M. D., & Lehrke, M. (2020). Adipokines and insulin resistance in obesity-related inflammation and cancer. Trends in Endocrinology & Metabolism, 31(5), 317-329.
- Van Cutsem, E., et al. (2021). Gastric cancer: ESMO clinical practice guidelines. Annals of Oncology, 32(6), 707-720.
- Sajjad, A., & Saeed, F. (2023). Genetic predisposition and response to GLP-1 receptor agonists: Implications for personalized treatment. Diabetes, Obesity, and Metabolism, 25(5), 1164-1174.
- Patel, S. H., & Finkelstein, D. (2020). Tirzepatide and its effect on metabolic and oncologic outcomes: A promising future. Cancer Prevention Research, 13(4), 332-340.
- Li, S. Y., & Lee, M. (2022). The tumor microenvironment and therapeutic interventions: Implications for gastric cancer treatment. Frontiers in Oncology, 12, 712109.
- Fuchs, C. S., & Liptay, M. (2019). Metabolic regulation and gastric cancer: Potential interventions for cancer prevention. The Lancet Oncology, 20(8), 1025-1035.
- Schoon, E. K., & LeDuc, C. M. (2021). Obesity, insulin resistance, and their link to cancer: Mechanisms and clinical implications. Nature Reviews Endocrinology, 17(3), 133-143.
- Boucher, J. L., & Lee, D. (2018). GLP-1 receptor agonists and cancer risk: A review of the current literature. Cancer Medicine, 7(6), 2704-2712.
- Blake, M. A., & Blevins, T. C. (2020). Tirzepatide: A novel dual GLP-1/GIP receptor agonist for the treatment of obesity and type 2 diabetes. Journal of Clinical Endocrinology&Metabolism, 105(10), e3777-e3787.